The following is an overview of the history of the effort to find a Vaccine for AIDS
National Institute of Allergy and Infectious Diseases created the following AIDS Vaccine historical overview (below). It can also be found here.
History of HIV Vaccine Research
||HIV was identified as the cause of AIDS.|
|1987||The first HIV vaccine clinical trial opened at the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland. This Phase I trial enrolled 138 healthy, uninfected volunteers. The gp160 subunit vaccine showed no serious adverse effects.|
|1988||The NIAID AIDS Vaccine Evaluation Group (AVEG), the first U.S. cooperative HIV vaccine clinical trials group, began enrolling volunteers in its first trial.|
|1992||NIAID launched the first Phase II HIV vaccine clinical trial. This trial included uninfected volunteers with a history of high-risk behavior — injection drug use, multiple sex partners, or sexually transmitted infections. Participants were counseled repeatedly to avoid any behaviors that put them at risk of HIV infection.|
|2004||VaxGen candidate failed in Phase III trials.|
|2007||NIAID halted the Phase II Step and Phambili studies due to safety concerns.|
|2011||HVTN 505 expanded to include protection from HIV as primary endpoint.|
|2012||Additional analyses of samples from RV144 provide insight about what type of immune response may be needed for an effective vaccine.|
|2013||HVTN 505 immunizations stopped due to lack of efficacy.|
National Institute of Allergy and Infectious Diseases created this AIDS Vaccine historical overview. It can also be found here.